title: [The efficacy of granisetron as a prophylactic anti-emetic agent used in conjunction with MCNU and VP16 chemotherapeutic regimens in the management of a pediatric case of hypothalamic anaplastic astrocytoma].
abstract: The management of a 12-year-old boy with hypothalamic anaplastic astrocytoma is reported herein. The pediatric patient underwent a subtotal removal of his brain tumor, and subsequently received multimodal treatment comprising radiotherapy (30.6 Gy to the whole brain and 50.4 Gy to the local lesion) and immunochemotherapy with MCNU (80 mg/m2, day 1), VP 16 (50 mg/day, days 2 to 6), and interferon-beta (3 x 10(6) units/day, initiating on day 2 for 4 weeks). The immunochemotherapy was given as of 4 weeks after radiotherapy. The administration of anti-cancer drugs caused severe nausea and vomiting, the intra-carotid infusion of MCNU being particularly emetogenic. The multi-modal treatment was then discontinued for a few weeks. A partial response was obtained, and the patient subsequently received 3 courses of maintenance therapy at six-month intervals using the same protocol as for the initial immunochemotherapy. During maintenance therapy, granisetron (40 micrograms/kg) was given intravenously 30 minutes before and one day after the injection of MCNU. Owing to the anti-emetic management of this patient, there were no complications throughout the chemotherapy. The patient has now survived for more than 3 years with a good quality of life, showing a Karnofsky performance score of 90.
authors.affiliation: Dept. of Neurosurgery, Shimane Medical University.
authors.forename: T
authors.initials: T
authors.lastname: Yamasaki
authors.forename: S
authors.initials: S
authors.lastname: Konishi
authors.forename: T
authors.initials: T
authors.lastname: Kagawa
authors.forename: H
authors.initials: H
authors.lastname: Nagai
authors.forename: S
authors.initials: S
authors.lastname: Nagao
authors.forename: K
authors.initials: K
authors.lastname: Moritake
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D017829:Granisetron / Q000627:therapeutic use*; D006801:Humans; D007029:Hypothalamic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D016899:Interferon-beta / Q000008:administration & dosage; D008297:Male; D009325:Nausea / Q000517:prevention & control*; D009607:Nitrosourea Compounds / Q000009:adverse effects; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D005047:Etoposide; D017829:Granisetron; D016899:Interferon-beta; D009607:Nitrosourea Compounds; C020766:ranimustine